CRYSTALLINE ANTIBODY FORMULATIONS
PROBLEM TO BE SOLVED: To provide anti-PCSK9 antibody crystals, and methods of making such antibody crystals and formulations comprising the antibody crystals.SOLUTION: The invention provides antibody crystals or formulations comprising the same. The anti-PCSK9 IgG can comprise the heavy and light ch...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | REENA J PATEL SARASWATHI MANDAPATI NAZER KHALAF |
| description | PROBLEM TO BE SOLVED: To provide anti-PCSK9 antibody crystals, and methods of making such antibody crystals and formulations comprising the antibody crystals.SOLUTION: The invention provides antibody crystals or formulations comprising the same. The anti-PCSK9 IgG can comprise the heavy and light chain complementary determining regions (CDRs) of antibody, 21B12. Thus, the antibody is an IgG comprising a light chain complementarity region (CDR) of the CDRL1 sequence, a CDRL2 of the CDRL2 sequence and a CDRL3 of the CDRL3 sequence in the 21B12 light chain variable region, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence, a CDRH2 of the CDRH2 sequence, and a CDRH3 of the CDRH3 sequence in the 21B12 heavy chain variable region.SELECTED DRAWING: Figure 1A
【課題】抗ＰＣＳＫ９抗体結晶、このような抗体結晶及び抗体結晶を含む製剤を作製する方法を提供すること。【解決手段】抗体結晶またはこれを含む製剤であって、抗ＰＣＳＫ９ ＩｇＧは、抗体、すなわち２１Ｂ１２の重鎖及び軽鎖相補性決定領域（ＣＤＲ）を含み得る。したがって、抗体は２１Ｂ１２軽鎖可変領域、におけるＣＤＲＬ１配列の軽鎖相補性領域（ＣＤＲ）、ＣＤＲＬ２配列のＣＤＲＬ２、ＣＤＲＬ３配列のＣＤＲＬ３、ならびに２１Ｂ１２重鎖可変領域ＣＤＲＨ１配列の重鎖相補性決定領域（ＣＤＲ）、ＣＤＲＨ２配列のＣＤＲＨ２、及びＣＤＲＨ３配列のＣＤＲＨ３を含むＩｇＧである。【選択図】図１Ａ |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2018150337A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2018150337A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2018150337A3</originalsourceid><addsrcrecordid>eNrjZFB0DooMDnH08fH0c1Vw9AvxdPJ3iVRw8w_yDfVxDPH09wvmYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBoYWhqYGxsbmjsZEKQIAg4Mi_w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CRYSTALLINE ANTIBODY FORMULATIONS</title><source>esp@cenet</source><creator>REENA J PATEL ; SARASWATHI MANDAPATI ; NAZER KHALAF</creator><creatorcontrib>REENA J PATEL ; SARASWATHI MANDAPATI ; NAZER KHALAF</creatorcontrib><description>PROBLEM TO BE SOLVED: To provide anti-PCSK9 antibody crystals, and methods of making such antibody crystals and formulations comprising the antibody crystals.SOLUTION: The invention provides antibody crystals or formulations comprising the same. The anti-PCSK9 IgG can comprise the heavy and light chain complementary determining regions (CDRs) of antibody, 21B12. Thus, the antibody is an IgG comprising a light chain complementarity region (CDR) of the CDRL1 sequence, a CDRL2 of the CDRL2 sequence and a CDRL3 of the CDRL3 sequence in the 21B12 light chain variable region, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence, a CDRH2 of the CDRH2 sequence, and a CDRH3 of the CDRH3 sequence in the 21B12 heavy chain variable region.SELECTED DRAWING: Figure 1A
【課題】抗ＰＣＳＫ９抗体結晶、このような抗体結晶及び抗体結晶を含む製剤を作製する方法を提供すること。【解決手段】抗体結晶またはこれを含む製剤であって、抗ＰＣＳＫ９ ＩｇＧは、抗体、すなわち２１Ｂ１２の重鎖及び軽鎖相補性決定領域（ＣＤＲ）を含み得る。したがって、抗体は２１Ｂ１２軽鎖可変領域、におけるＣＤＲＬ１配列の軽鎖相補性領域（ＣＤＲ）、ＣＤＲＬ２配列のＣＤＲＬ２、ＣＤＲＬ３配列のＣＤＲＬ３、ならびに２１Ｂ１２重鎖可変領域ＣＤＲＨ１配列の重鎖相補性決定領域（ＣＤＲ）、ＣＤＲＨ２配列のＣＤＲＨ２、及びＣＤＲＨ３配列のＣＤＲＨ３を含むＩｇＧである。【選択図】図１Ａ</description><language>eng ; jpn</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180927&DB=EPODOC&CC=JP&NR=2018150337A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180927&DB=EPODOC&CC=JP&NR=2018150337A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>REENA J PATEL</creatorcontrib><creatorcontrib>SARASWATHI MANDAPATI</creatorcontrib><creatorcontrib>NAZER KHALAF</creatorcontrib><title>CRYSTALLINE ANTIBODY FORMULATIONS</title><description>PROBLEM TO BE SOLVED: To provide anti-PCSK9 antibody crystals, and methods of making such antibody crystals and formulations comprising the antibody crystals.SOLUTION: The invention provides antibody crystals or formulations comprising the same. The anti-PCSK9 IgG can comprise the heavy and light chain complementary determining regions (CDRs) of antibody, 21B12. Thus, the antibody is an IgG comprising a light chain complementarity region (CDR) of the CDRL1 sequence, a CDRL2 of the CDRL2 sequence and a CDRL3 of the CDRL3 sequence in the 21B12 light chain variable region, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence, a CDRH2 of the CDRH2 sequence, and a CDRH3 of the CDRH3 sequence in the 21B12 heavy chain variable region.SELECTED DRAWING: Figure 1A
【課題】抗ＰＣＳＫ９抗体結晶、このような抗体結晶及び抗体結晶を含む製剤を作製する方法を提供すること。【解決手段】抗体結晶またはこれを含む製剤であって、抗ＰＣＳＫ９ ＩｇＧは、抗体、すなわち２１Ｂ１２の重鎖及び軽鎖相補性決定領域（ＣＤＲ）を含み得る。したがって、抗体は２１Ｂ１２軽鎖可変領域、におけるＣＤＲＬ１配列の軽鎖相補性領域（ＣＤＲ）、ＣＤＲＬ２配列のＣＤＲＬ２、ＣＤＲＬ３配列のＣＤＲＬ３、ならびに２１Ｂ１２重鎖可変領域ＣＤＲＨ１配列の重鎖相補性決定領域（ＣＤＲ）、ＣＤＲＨ２配列のＣＤＲＨ２、及びＣＤＲＨ３配列のＣＤＲＨ３を含むＩｇＧである。【選択図】図１Ａ</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFB0DooMDnH08fH0c1Vw9AvxdPJ3iVRw8w_yDfVxDPH09wvmYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBoYWhqYGxsbmjsZEKQIAg4Mi_w</recordid><startdate>20180927</startdate><enddate>20180927</enddate><creator>REENA J PATEL</creator><creator>SARASWATHI MANDAPATI</creator><creator>NAZER KHALAF</creator><scope>EVB</scope></search><sort><creationdate>20180927</creationdate><title>CRYSTALLINE ANTIBODY FORMULATIONS</title><author>REENA J PATEL ; SARASWATHI MANDAPATI ; NAZER KHALAF</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2018150337A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2018</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>REENA J PATEL</creatorcontrib><creatorcontrib>SARASWATHI MANDAPATI</creatorcontrib><creatorcontrib>NAZER KHALAF</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>REENA J PATEL</au><au>SARASWATHI MANDAPATI</au><au>NAZER KHALAF</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CRYSTALLINE ANTIBODY FORMULATIONS</title><date>2018-09-27</date><risdate>2018</risdate><abstract>PROBLEM TO BE SOLVED: To provide anti-PCSK9 antibody crystals, and methods of making such antibody crystals and formulations comprising the antibody crystals.SOLUTION: The invention provides antibody crystals or formulations comprising the same. The anti-PCSK9 IgG can comprise the heavy and light chain complementary determining regions (CDRs) of antibody, 21B12. Thus, the antibody is an IgG comprising a light chain complementarity region (CDR) of the CDRL1 sequence, a CDRL2 of the CDRL2 sequence and a CDRL3 of the CDRL3 sequence in the 21B12 light chain variable region, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence, a CDRH2 of the CDRH2 sequence, and a CDRH3 of the CDRH3 sequence in the 21B12 heavy chain variable region.SELECTED DRAWING: Figure 1A
【課題】抗ＰＣＳＫ９抗体結晶、このような抗体結晶及び抗体結晶を含む製剤を作製する方法を提供すること。【解決手段】抗体結晶またはこれを含む製剤であって、抗ＰＣＳＫ９ ＩｇＧは、抗体、すなわち２１Ｂ１２の重鎖及び軽鎖相補性決定領域（ＣＤＲ）を含み得る。したがって、抗体は２１Ｂ１２軽鎖可変領域、におけるＣＤＲＬ１配列の軽鎖相補性領域（ＣＤＲ）、ＣＤＲＬ２配列のＣＤＲＬ２、ＣＤＲＬ３配列のＣＤＲＬ３、ならびに２１Ｂ１２重鎖可変領域ＣＤＲＨ１配列の重鎖相補性決定領域（ＣＤＲ）、ＣＤＲＨ２配列のＣＤＲＨ２、及びＣＤＲＨ３配列のＣＤＲＨ３を含むＩｇＧである。【選択図】図１Ａ</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; jpn |
| recordid | cdi_epo_espacenet_JP2018150337A |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | CRYSTALLINE ANTIBODY FORMULATIONS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T10%3A34%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=REENA%20J%20PATEL&rft.date=2018-09-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2018150337A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |